Rob Schott
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Rob Schott
Sangamo Therapeutics, Inc reported in an 8-K filed August 9, 2022 that Rob Schott resigned as Senior Vice President, Head of Development, effective August 19, 2022.
“On August 8, 2022, Rob Schott, M.D., M.P.H., F.A.C.C., Senior Vice President, Head of Development of Sangamo Therapeutics, Inc. (the "Company"), notified the Company of his resignation from this position and from his employment with the Company, with such resignation to be effective on August 19, 2022, in order to pursue a new opportunity.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Sangamo Therapeutics, Inc (SGMOQ)
Transcript header (unverified)
Start not stated–2022-08-19
Company network
Recorded roles and call appearances connecting this person to public companies.
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.